TYK2 and IL‐23 Pathway Therapies in Psoriasis: Associations With IL‐6, Tryptophan Metabolism, and Depressive Symptoms
These findings provide a hypothesis that TYK2 inhibitors disrupt the persistent "peripheral inflammation-central depression" cycle by targeting the IL-23/Th17 axis and modulating the IL-6/tryptophan metabolic hub. This innovative, multi-targeted approach represents a possibility for treating psoriasis with comorbid depression, offering not only clinical improvements in both skin and mood symptoms but also enhanced patient adherence to treatment regimens.
Authors
- HW Huang
- Kexiang Yan (ORCID: https://orcid.org/0000-0003-1295-2626)
- Junhao Zhu (ORCID: https://orcid.org/0009-0009-0768-6870)
- JG Xu
- Lanmei Lin (ORCID: https://orcid.org/0000-0002-3769-2624)
- Nan Yu (ORCID: https://orcid.org/0000-0002-8609-7362)
- Jiayu Sun (ORCID: https://orcid.org/0000-0002-0920-5948)
- Xiaonian Lu
- Gujie Wu (ORCID: https://orcid.org/0009-0002-6705-0857)
- Chenghui Zheng
- Xinyi Zhu (ORCID: https://orcid.org/0009-0009-5228-8978)
- Canbin Dong
- Juan Du
- Yilun Wang
- Bingjie Tian
- Xiaoniu Liang
Institutions
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- Ningxia Medical University (CN)
- Ningxia Medical University General Hospital (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- International Journal of Dermatology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1111/ijd.70230
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00